InterCure Ltd. today announced its international expansion into Europe through a partnership with iconic cannabis brand Cookies. The parties entered into a multi-year agreement under which InterCure expects to establish Cookies stores and medical cannabis pharmacies in Austria and the United Kingdom in early 2022, subject to local regulations.
“As we focus on new territories, it’s vital our customers continue to count on the quality Cookies is known for, which is a value we share with our partners at InterCure,” said Parker Berling, President of Cookies.
“We look forward to reaching audiences in Austria and the United Kingdom and establishing Cookies as a mainstay in each community.”
InterCure, a Cookies’ international partner, is already cultivating, manufacturing and distributing Cookies’ GMP standard, branded products through its Cookies’ national medical cannabis pharmacy chain in Israel. InterCure will leverage its licensed international supply chain to serve the growing communities of medical cannabis patients in Europe.
“Cookies is already one of the most internationally recognized cannabis brands,” said InterCure’s Chief Executive Officer, Alexander Rabinovitch.
“With our mutual success in Israel, it’s logical for us to further expand into Europe by duplicating our winning model. As European markets evolve and regulations continue to become more favorable for cannabis companies, we expect to expand into new territories and provide our customers with the highest quality pharmaceutical grade cannabis products.”
